Benzinga: Lantern Pharma CEO Discusses The Addition Of Its New ADC Program And The Resurgence Of ADC Therapy For Cancer Treatment

Saved in:
Bibliographic Details
Published inNewstex Finance & Accounting Blogs
Main Author Tenn, Jaycee
Format Web Resource
LanguageEnglish
Published Chatham Newstex 22.02.2021
Subjects
Antibodies
Cancer therapies
Drugs
FDA approval
Manufacturing
Medical research
Tumors
Writers
Online AccessGet full text

Cover

More Information
Bibliography:ObjectType-Blog-1
SourceType-Blogs, Podcasts, & Websites-1
content type line 39